Thyroid Function Abnormalities in Patients Receiving Anticancer Agents

Torino, Francesco; Barnabei, Agnese; Baldelli, Roberto; Appetecchia, Marialuisa

doi:10.5772/50375

Cited by 4 publications

(2 citation statements)

References 163 publications

(235 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The landscape of THs actions is further complicated by the emerging role of THs metabolites in cancer [ 16 , 17 ]. The clinical relevance of hypothyroidism in patients with solid non-thyroid cancer shares many complex characteristics with hypothyroidism in the general population [ 18 , 19 ], but the former is even more complicated than the latter due to distinct issues arising from the hypothyroidism–cancer association [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ].…”

Section: Introductionmentioning

confidence: 99%

“…A notable number of cancer patients are expected to confront the hypothyroidism–cancer association, given that hypothyroidism constitutes a common adverse effect of innovative anticancer treatments [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ] and diagnostic procedures using iodinated contrast media [ 34 ], which have, currently, revolutionized the standard of cancer care. Hopefully, hypothyroidism that is induced by the administration of iodinated contrast media is not general and is transient, being attributed to the suppression of THs synthesis via the Wolff–Chaikoff mechanism—an effect that lasts only a few weeks.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum

Deligiorgi

Trafalis

2022

JCM

View full text Add to dashboard Cite

Hypothyroidism in patients with solid non-thyroid cancer is a tantalizing entity, integrating an intriguing thyroid hormones (THs)–cancer association with the complexity of hypothyroidism itself. The present narrative review provides a comprehensive overview of the clinical relevance of hypothyroidism in solid non-thyroid cancer. Hypothyroidism in patients with solid non-thyroid cancer is reminiscent of hypothyroidism in the general population, yet also poses distinct challenges due to the dual role of THs in cancer: promoting versus inhibitory. Close collaboration between oncologists and endocrinologists will enable the prompt and personalized diagnosis and treatment of hypothyroidism in patients with solid non-thyroid cancer. Clinical data indicate that hypothyroidism is a predictor of a decreased or increased risk of solid non-thyroid cancer and is a prognostic factor of favorable or unfavorable prognosis in solid non-thyroid cancer. However, the impact of hypothyroidism with respect to the risk and/or prognosis of solid non-thyroid cancer is not a consistent finding. To harness hypothyroidism, or THs replacement, as a personalized anticancer strategy for solid non-thyroid cancer, four prerequisites need to be fulfilled, namely: (i) deciphering the dual THs actions in cancer; (ii) identifying interventions in THs status and developing agents that block tumor-promoting THs actions and/or mimic anticancer THs actions; (iii) appropriate patient selection; and (iv) counteracting current methodological limitations.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum

Deligiorgi

Trafalis

2022

JCM

View full text Add to dashboard Cite

show abstract

Early manifestation of mild cognitive impairment in B-cell non-Hodgkin’s lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy

Khan

Garg

Bhurani

et al. 2016

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Existing evidence suggests that pro-inflammatory cytokines increases during chemotherapy which plays an intermediary role in Chemotherapy related cognitive impairment (CRCI) and thyroid dysregulation. Previous studies suggest that thyroid hormones are essential for neuronal development and neurotransmitter release. CHOP regimen has been the backbone of Non-Hodgkin's lymphoma (NHL) treatment from a decade but rituximab addition to CHOP (R-CHOP) has improved cure rates. However, their adverse event profile on behavior is not well studied on patients. In this study total 68 NHL patients were enrolled and divided equally in 2 groups as CHOP receiving (n = 34) and R-CHOP receiving (n = 34). Effects of R-CHOP and CHOP regimen on thyroid function, pro-inflammatory cytokines and cognitive function were determined at four time points that was from one day before 1st (TP0), 2nd (TP1), 3rd (TP2) and 4th (TP3) cycle of chemotherapy. Results indicated significant increase in levels of pro-inflammatory cytokines after each time point from TP0 to TP3of chemotherapy. Thyroid hormone levels i.e. T3, T4 were found significantly decreased and TSH was increased after each time point of both groups. MMSE score was found significantly decreased after each cycle of both groups. However, an inverse association was found between IL-1β levels with TSH by applying correlation coefficient. Cognitive function was decreased in patients with decreased T3 and T4 levels and increased TSH. To conclude, patients receiving R-CHOP regimen were found to have more increased IL-6 and IL-1β with more cognitive decline and thyroid abnormality as comparison to CHOP receiving patients.

show abstract

The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists

Deligiorgi

Trafalis

2022

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Thyroid Function Abnormalities in Patients Receiving Anticancer Agents

Cited by 4 publications

References 163 publications

The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum

The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum

Early manifestation of mild cognitive impairment in B-cell non-Hodgkin’s lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy

The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists

Contact Info

Product

Resources

About